Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
Authors:
- 15 October 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (20) , 6515-6524
Abstract
Purpose: There is an interest in the discovery of biopharmaceuticals, which are well tolerated and which potentiate the action of anthracyclines and taxanes in breast cancer therapy.Experimental Design: We have produced a recombinant fusion protein, composed of the human antibody fragment scFv(F16) fused to human interleukin-2 (F16-IL2), and tested its therapeutic performance in the MDA-MB-231 xenograft model of human breast cancer. The F16 antibody is specific to the alternatively spliced A1 domain of tenascin-C, which is virtually undetectable in normal tissues but is strongly expressed in the neovasculature and stroma of breast cancer.Results: When used as monotherapy, F16-IL2 displayed a strikingly superior therapeutic benefit compared with unconjugated recombinant IL-2. The administration of doxorubicin either before (8 days, 24 h, or 2 h) or simultaneously with the injection of F16-IL2 did not decrease the accumulation of immunocytokine in the tumor as measured by quantitative biodistribution analysis. Therapy experiments, featuring five once per week coadministrations of 20 μg F16-IL2 and doxorubicin, showed a statistically significant reduction of tumor growth rate and prolongation of survival at a 4 mg/kg doxorubicin dose but not at a 1 mg/kg dose. By contrast, combination of F16-IL2 with paclitaxel (5 and 1 mg/kg) exhibited a significant therapeutic benefit compared with paclitaxel alone at both dose levels. F16-IL2, alone or in combination with doxorubicin, was well tolerated in cynomolgus monkeys at doses equivalent to the ones now used in clinical studies.Conclusions: F16-IL2 may represent a new useful biopharmaceutical for the treatment of breast cancer.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxelBritish Journal of Cancer, 2007
- Ligand‐Based Vascular Targeting of DiseaseChemMedChem, 2006
- Molecularly targeted therapy for melanomaCancer, 2006
- Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19)Nuclear Medicine and Biology, 2006
- Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladderJournal of Cancer Research and Clinical Oncology, 2006
- Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic OriginClinical Cancer Research, 2006
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005
- Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant AntibodyThe American Journal of Pathology, 1999
- Production and characterization of monoclonal antibodies specific for different epitopes of human tenascinFEBS Letters, 1993
- By-passing immunisationJournal of Molecular Biology, 1992